As of May 11, 2026, Intuitive Surgical (ISRG) stock has experienced a significant decline, falling nearly 20% year-to-date (YTD) to hit 52-week lows, with shares recently dropping to roughly \(\$419-\$427\). Despite beating revenue expectations for Q1 2026, the stock has been pressured by a combination of regulatory issues, rising costs, and high valuation concerns. [1, 2, 3]
Key Reasons for the Stock Drop:
- FDA Safety Alerts and Recalls: The primary catalyst for recent sharp declines is a Class I recall by the FDA for specific 8mm SureForm 30 staplers, which has raised concerns over product liability and safety.
- Margin Pressures & Costs: While the company reported strong revenue, increased costs related to the launch of their new da Vinci 5 platform, higher manufacturing costs, and potential, rising tariffs have compressed operating margins.
- Intensifying Competition: Competition in international markets, particularly in China, is intensifying. Local manufacturers are gaining traction with lower-cost robotic systems, threatening ISRG’s market share in the longer term.
- Valuation Concerns & Institutional Selling: Large institutional investors have been trimming their positions, prompting concerns that the stock was overvalued relative to its short-term growth potential, even with a strong long-term outlook.
- Macroeconomic Headwinds: Reduced hospital capital spending due to budget constraints, particularly in Japan and the UK, has created headwinds for new system placements.
